THE NICKLES GROUP, LLC

Lobbying for OMEROS CORPORATION · Biopharmaceutical company.

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 15, 2026

Money reported

None

Registrations and no-activity reports carry no figure.

Client based in

Washington

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 2

Medicare/Medicaid

Monitored separate payment policy for nonopioid alternatives. Monitored issues involving rare disease therapies.

Health Issues

Monitored issues related to rare pediatric disease and Priority Review Vouchers (PRVs).

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.